Related Experiment Video
Updated: Oct 12, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
Published on: March 6, 2018
Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network meta-analysis
Juan Victor Ariel Franco1, Jae Hung Jung2,3, Mari Imamura4
1Associate Cochrane Centre, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Minimally invasive treatments for benign prostatic hyperplasia (BPH) show mixed results for lower urinary tract symptoms (LUTS). While some offer fewer adverse events than transurethral resection of the prostate (TURP), others may worsen symptoms.
Area of Science:
- Urology
- Surgical Innovation
Background:
- Benign prostatic hyperplasia (BPH) commonly causes lower urinary tract symptoms (LUTS) in men.
- Minimally invasive treatments (MITs) offer alternatives to traditional surgery like transurethral resection of the prostate (TURP).
Purpose of the Study:
- To compare the effectiveness and rank various MITs for LUTS in BPH.
- To evaluate MITs against TURP and sham surgery.
Main Methods:
- A frequentist network meta-analysis of 27 randomized controlled trials (RCTs) involving 3017 men.
- Included treatments: convective radiofrequency water vapour thermal therapy (WVTT), prostatic arterial embolization (PAE), prostatic urethral lift (PUL), temporary implantable nitinol device (TIND), and transurethral microwave thermotherapy (TUMT).
Main Results:
- Most evidence had low to very low certainty (GRADE).
- Compared to TURP, PUL and PAE showed little symptom difference; WVTT, TUMT, and TIND showed worse symptoms.
- MITs generally reduced major adverse events versus TURP but had uncertain effects on sexual function.
Conclusions:
- MITs may offer similar or worse outcomes for urinary symptoms and quality of life compared to TURP in the short term.
- Prostatic urethral lift (PUL) and prostatic arterial embolization (PAE) showed potential for efficacy in urinary symptoms and quality of life among MITs.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Urinary Tract Calculi VI: Surgical Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

